Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The Ebola outbreak in DR Congo has risen to 1,427 cases, while the death toll has climbed to 440, according to the latest government data.

More than 609 patients are hospitalized in Congo, while many have also recovered. Uganda has so far reported 20 confirmed cases and two deaths. There has also been one case in France and another in a US citizen medically evacuated to Germany, both believed to have been imported from areas affected by the ongoing outbreak.

The Ebola virus disease, caused by the Bundibugyo strain, has no approved vaccine or treatment.

"Even without approved therapeutics, people are recovering from this disease, but, of course, we could save many more lives with safe and effective therapeutics in our toolkit," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

He said this while announcing the launch of the clinical trial of two therapeutics, with the enrolment of the first patient.

"The PARTNERS trial will evaluate the monoclonal antibody MBP134 and the antiviral drug remdesivir, alone and in combination," he added.

Also read: Donald Trump Posts AI Video of Himself Treating Critics for 'Derangement Syndrome'

All About the Trial

The study is being coordinated by the DRC's National Institute for Biomedical Research, supported by a coalition of partners including WHO, and conducted in close cooperation with the affected communities.

According to Tedros, patients who enroll in the trial will receive comprehensive supportive care and close follow-up.

"We are also working to ensure they have access to the two drugs should they prove safe and efficacious in the trial."

In addition, the WHO has granted emergency use listing to the first molecular diagnostic test for Bundibugyo virus.

Further, the antiviral drug remdesivir, marketed as Veklury is also expected to start. Remdesivir became widely known during the COVID-19 pandemic and is being evaluated to determine whether it can improve outcomes when combined with the antibody treatment.

As per experts, it could take months, and possibly as many as 1,000 study participants, to determine whether either drug works.

Currently, the study is being offered only at one Ebola treatment center in Congo's Ituri province. The region has been heavily affected by violence, including attacks on healthcare workers responding to a virus spread through contact with infected patients' bodily fluids. Officials plan to expand the trial to other locations once it is safe to do so.

Read More: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?

Challenges Remain

Tedros said that despite the progress, significant challenges remain, including mistrust and violence.

This week, an Ebola treatment center in Ituri province was attacked, resulting in the deaths of two people. The center was set on fire, and patients fled.

Such acts not only endanger patients and health workers but also impede efforts to stop transmission and save lives.

He added that the complexity of the outbreak requires close coordination across the United Nations system.

What Is Ebola?

Ebola is a severe and often fatal viral hemorrhagic fever first identified in 1976. Since then, more than 30 outbreaks have been recorded, primarily in Central and West Africa.

Common Symptoms of Ebola

• Fever
• Headache
• Weakness and fatigue
• Vomiting
• Diarrhea
• Muscle pain
• Sore throat
• Unexplained bleeding or bruising.

Amid increasing conversations about Donald Trump suffering from dementia, the US President posted an AI-generated video of himself as a doctor diagnosing celebrities with what he calls "Trump Derangement Syndrome (TDS)."

The clip features AI recreations of Hollywood actors and celebrities, including Whoopi Goldberg, Robert De Niro, Julia Roberts and Rosie O'Donnell, all of whom have previously criticized Trump.

"Have you or someone you know been diagnosed with TDS?" the AI Trump asks at the start of the clip posted on Truth Social.

Calling the "symptoms relentless," the 80-year-old President said that "fortunately, I'm Doctor Trump, and I have a treatment plan," The Independent reported.

Trump's AI Patients Share Their Symptoms

The AI-generated Trump then invited viewers to hear from some of his "patients."

"I couldn't eat, I couldn't sleep, constantly angry…" the fake De Niro said. "I made everyone miserable around me."

"I feel like I've aged 20 years in the last two years," added the AI version of Roberts, claiming that she was starting to "worry about her future."

The fake O'Donnell claimed that she had been "suffering for over a decade," while the AI Goldberg said she believed she was a "lost cause."

Other stars spoofed in the 90-second clip include actors Edward Norton and John Leguizamo, both of whom have criticized the president.

Also read: Norovirus Hits Princess Cruise Ship; US CDC Reports 5th Stomach Bug Outbreak of 2026

'Doctor Trump's Treatment Plan

At the end of the video, "Doctor Trump" revealed his "treatment" plan: "Turn off fake news."

He further instructed the AI patients to: "Say your prayers and, if you ever feel anxious, just have a Diet Coke like me and you're gonna see a remarkable difference in your life."

What Is Trump Derangement Syndrome?

READ: Scientific Breakthrough: US Scientists Create First Synthetic Cell That Eats and Reproduces

Trump has often labeled his detractors as having Trump Derangement Syndrome, even claiming in the Oval Office that he had heard it "actually is a disease."

The term is an adaptation of "Bush Derangement Syndrome," which was coined by columnist Charles Krauthammer in 2003.

Krauthammer described the term as "the acute onset of paranoia in otherwise normal people in reaction to the policies, the presidency—nay—the very existence of George W. Bush."

Trump's Health Under Scrutiny

Read More: New Book Examines Donald Trump's Health, Age Concerns; White House Responds

Trump, who became the oldest US president in history after turning 80 this year, has faced growing public scrutiny over his health.

Recent public appearances have prompted speculation after observers noted swollen ankles, bruising on his hands, verbal slips and occasional episodes in which he appeared drowsy during meetings and international summits.

Some physicians have also publicly expressed concerns about the president's physical and cognitive health, although none have diagnosed him with dementia.

But Trump has repeatedly rejected allegations of cognitive decline or other serious health issues. His most recent annual physical examination also concluded him to be "in excellent health."

The White House also maintains that: "President Trump is the sharpest and most accessible President in American history who is working nonstop to solve problems and deliver on his promises."

The US Centers for Disease Control and Prevention (CDC) has reported another norovirus outbreak aboard a Cruise ship that has sickened nearly 125 people.

So far this year, the CDC has reported seven outbreaks on cruise ships under its jurisdiction, five of which were caused by norovirus.

Nearly 125 People Fall Ill

The outbreak occurred aboard the Ruby Princess during a 20-day voyage along the west coast of North America.

According to the CDC, 102 passengers and 23 crew members reported gastrointestinal illness during the voyage.

The outbreak was first reported to the CDC's Vessel Sanitation Program on June 28.

The Ruby Princess was carrying more than 3,000 passengers and 1,144 crew members during the outbreak.

According to the CDC, Princess Cruises and the ship's crew implemented increased cleaning and disinfection procedures under the company's outbreak prevention and response plan.

Crew members also collected stool specimens from affected individuals for testing, isolated ill passengers and crew members, and consulted with the CDC's Vessel Sanitation Program.

Also read: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?

What Is Norovirus?

Norovirus is a highly contagious virus that causes gastroenteritis, leading to inflammation of the stomach and intestines.

Speaking to HealthandMe, epidemiologist Dr. Amitav Banerjee, professor at DY Patil Vidyapeeth, Pune, described norovirus as “notorious because it spreads very fast.”

“It can spread through fomites like handles and knobs, and even a very low infectious dose—around 18 viral particles—can cause infection. So it spreads very fast,” he said.

He added that while many common disinfectants are ineffective against it, norovirus can be inactivated using bleach and chlorine-based cleaning agents.

Is The Norovirus Outbreak Of Concern?

Although outbreaks can look alarming, Dr. Banerjee emphasized that norovirus infections are generally self-limiting.

“In the ship, it can be managed with oral rehydration, and in severe cases, IV fluids can help prevent complications and mortality,” he said.

Dr. Banerjee also clarified that, unlike diseases with pandemic potential, norovirus outbreaks—while explosive in nature—do not typically pose a long-term global threat.

"Norovirus is a stomach infection contracted through the consumption of contaminated food or water or through contact with an infected individual. The infection is highly contagious, but not life-threatening, and is manageable with proper care and hydration," Dr Suresh Kumar D, Senior Specialist - Infectious Diseases, Apollo Speciality Hospitals, Vanagaram, Chennai, told HealthandMe.

Who Is Most at Risk? What Are The Key Symptoms

Dr. Banerjee noted that extreme age groups, especially very young infants and the elderly, are at higher risk due to dehydration from diarrheal illness. However, deaths remain rare when proper care is provided.

Norovirus illnesses usually last between two and three days. Symptoms usually begin suddenly within 12 to 48 hours of exposure and may include:

• Nausea
• Vomiting
• Watery diarrhea
• Stomach cramps
• Low-grade fever
• Headache and body aches
• Fatigue

What You Can Do To Stop Its Spread

Because of how fast viruses spread, experts highly recommend preventive actions such as:

• Wash your hands frequently with soap and warm water, especially after using the toilet or before preparing food.
• Avoid visiting hospitals or care homes if experiencing symptoms.
• Stay home for at least 48 hours after symptoms subside to prevent spreading the virus.